Heartflow (NASDAQ:HTFL) Major Shareholder Sells $23,411,796.21 in Stock

Heartflow, Inc. (NASDAQ:HTFL) major shareholder Bain Capital Life Sciences Inv sold 797,133 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $29.37, for a total value of $23,411,796.21. Following the transaction, the insider owned 9,396,915 shares in the company, valued at $275,987,393.55. This represents a 7.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bain Capital Life Sciences Inv also recently made the following trade(s):

• On Thursday, April 30th, Bain Capital Life Sciences Inv sold 948,757 shares of Heartflow stock. The stock was sold at an average price of $29.23, for a total value of $27,732,167.11.
• On Tuesday, April 28th, Bain Capital Life Sciences Inv sold 254,110 shares of Heartflow stock. The shares were sold at an average price of $30.51, for a total value of $7,752,896.10.
• On Wednesday, February 4th, Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock. The shares were sold at an average price of $28.05, for a total value of $56,100,000.00.

Heartflow Price Performance

Shares of Heartflow stock opened at $28.67 on Friday. The business has a 50 day simple moving average of $26.11 and a two-hundred day simple moving average of $29.25. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22. The stock has a market capitalization of $2.47 billion and a P/E ratio of -14.41.

Institutional Investors Weigh In On Heartflow

Several hedge funds and other institutional investors have recently made changes to their positions in HTFL. Wellington Management Group LLP acquired a new stake in shares of Heartflow in the third quarter valued at approximately $164,263,000. Baillie Gifford & Co. acquired a new stake in shares of Heartflow in the third quarter valued at approximately $101,182,000. Schusterman Interests LLC acquired a new stake in shares of Heartflow in the third quarter valued at approximately $65,274,000. Capricorn Investment Group LLC acquired a new stake in shares of Heartflow in the fourth quarter valued at approximately $48,178,000. Finally, Vanguard Group Inc. acquired a new stake in shares of Heartflow in the third quarter valued at approximately $48,871,000.

Wall Street Analysts Forecast Growth

HTFL has been the subject of a number of research analyst reports. Canaccord Genuity Group increased their target price on Heartflow from $40.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, March 19th. JPMorgan Chase & Co. reduced their target price on Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, March 19th. Finally, Wells Fargo & Company reduced their target price on Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, March 19th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.